Hey narmac, I never said I thought funds weren't interested, just that between science risk, currently zero epigenetic therapies in use, and market risk that RVX is a challenging investment to make for a fund. That coupled with the fact that RVX is a long way off ph3 results and the company is very poor at sharing its story to me put it in the "what's the hurry" category of investment for large money. I doubt very much that KD being a "wild card" even registers a blip on the radar. I haven't searched exhaustively by any means but I haven't found any evidence that would suggest that Eastern or Dart Neuroscience has been a problem shareholder in their other biotech investments. I didn't say there are "lots of alternatives to clear the debt", just one obvious one to deal with the debt that would be far less dilutive than doing a financing to clear it. Giving Eastern, or for that matter Hepalink, 7 or 8 million warrants (the prior cost roughly) for guarantee extensions would be far less dilutive than issuing 40 to 45 million shares, at current pricing, to settle the debt. Additionally, I really don't think that Eastern would want to have to pay 68 million dollars to settle the RVX debt to get some of RVX's IP and then have to go to work to prove it up. I'm fairly sure that Eastern would much prefer to see RVX be very successful and in turn their existing 20 something percent ownership in the company pay off handsomely. Jmo